JPWO2023038030A1 - - Google Patents
Info
- Publication number
- JPWO2023038030A1 JPWO2023038030A1 JP2023546948A JP2023546948A JPWO2023038030A1 JP WO2023038030 A1 JPWO2023038030 A1 JP WO2023038030A1 JP 2023546948 A JP2023546948 A JP 2023546948A JP 2023546948 A JP2023546948 A JP 2023546948A JP WO2023038030 A1 JPWO2023038030 A1 JP WO2023038030A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021146389 | 2021-09-08 | ||
| JP2021146389 | 2021-09-08 | ||
| PCT/JP2022/033458 WO2023038030A1 (ja) | 2021-09-08 | 2022-09-06 | 固形腫瘍治療用医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2023038030A1 true JPWO2023038030A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2023-03-16 |
| JPWO2023038030A5 JPWO2023038030A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2023-11-27 |
| JP7445826B2 JP7445826B2 (ja) | 2024-03-07 |
Family
ID=85507597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023546948A Active JP7445826B2 (ja) | 2021-09-08 | 2022-09-06 | 固形腫瘍治療用医薬組成物 |
Country Status (10)
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110288115A1 (en) * | 2010-05-24 | 2011-11-24 | Avmedis Llc | Treatment of vagally-mediated spectrum disorders |
| WO2015098853A1 (ja) * | 2013-12-25 | 2015-07-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | （６Ｓ，９ａＳ）－Ｎ－ベンジル－６－［（４－ヒドロキシフェニル）メチル］－４，７－ジオキソ－８－（｛６－［３－（ピペラジン－１－イル）アゼチジン－１－イル］ピリジン－２－イル｝メチル）－２－（プロプ－２－エン－１－イル）－オクタヒドロ－１Ｈ－ピラジノ［２，１－ｃ］［１，２，４］トリアジン－１－カルボキサミド化合物 |
| WO2018147275A1 (ja) * | 2017-02-08 | 2018-08-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
| WO2021086909A1 (en) * | 2019-10-29 | 2021-05-06 | Eisai R&D Managment Co., Ltd. | Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014168986A1 (en) * | 2013-04-08 | 2014-10-16 | Brown Dennis M | Therapeutic benefit of suboptimally administered chemical compounds |
| CN105764502A (zh) * | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群及其类似物及衍生物的治疗益处的组合方法 |
| ES2870013T3 (es) | 2015-06-23 | 2021-10-26 | Eisai R&D Man Co Ltd | Cristal de (6S,9aS)-N-bencil-8-({6-[3-(4-etilpiperazin-1-il)azetidin-1-il]piridin-2-il}metil)-6-(2-fluoro-4-hidroxibencil)-4,7-dioxo-2-(prop-2-en-1-il)hexahidro-2H-pirazino[2,1-c][1,2,4]triazin-1(6H)-carboxamida |
-
2022
- 2022-09-06 TW TW111133779A patent/TW202327613A/zh unknown
- 2022-09-06 KR KR1020247003704A patent/KR20240056487A/ko active Pending
- 2022-09-06 CN CN202280052902.2A patent/CN117794544A/zh active Pending
- 2022-09-06 AU AU2022342537A patent/AU2022342537A1/en active Pending
- 2022-09-06 EP EP22867352.1A patent/EP4364742A4/en active Pending
- 2022-09-06 JP JP2023546948A patent/JP7445826B2/ja active Active
- 2022-09-06 MX MX2024002060A patent/MX2024002060A/es unknown
- 2022-09-06 WO PCT/JP2022/033458 patent/WO2023038030A1/ja not_active Ceased
- 2022-09-06 CA CA3227813A patent/CA3227813A1/en active Pending
- 2022-09-06 US US18/293,848 patent/US20250222003A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110288115A1 (en) * | 2010-05-24 | 2011-11-24 | Avmedis Llc | Treatment of vagally-mediated spectrum disorders |
| WO2015098853A1 (ja) * | 2013-12-25 | 2015-07-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | （６Ｓ，９ａＳ）－Ｎ－ベンジル－６－［（４－ヒドロキシフェニル）メチル］－４，７－ジオキソ－８－（｛６－［３－（ピペラジン－１－イル）アゼチジン－１－イル］ピリジン－２－イル｝メチル）－２－（プロプ－２－エン－１－イル）－オクタヒドロ－１Ｈ－ピラジノ［２，１－ｃ］［１，２，４］トリアジン－１－カルボキサミド化合物 |
| WO2018147275A1 (ja) * | 2017-02-08 | 2018-08-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
| WO2021086909A1 (en) * | 2019-10-29 | 2021-05-06 | Eisai R&D Managment Co., Ltd. | Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022342537A1 (en) | 2024-02-15 |
| TW202327613A (zh) | 2023-07-16 |
| WO2023038030A1 (ja) | 2023-03-16 |
| MX2024002060A (es) | 2024-03-01 |
| JP7445826B2 (ja) | 2024-03-07 |
| EP4364742A1 (en) | 2024-05-08 |
| EP4364742A4 (en) | 2025-07-02 |
| CA3227813A1 (en) | 2023-03-16 |
| CN117794544A (zh) | 2024-03-29 |
| US20250222003A1 (en) | 2025-07-10 |
| KR20240056487A (ko) | 2024-04-30 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231006 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231006 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20231006 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231107 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240220 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240226 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7445826 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |